28bio updates existing equity offering to $8.52 million
The renamed AxoSim reported a fully subscribed offering first disclosed in June 2025.
28bio reported $8,524,945 in cumulative equity securities sales in an amendment filed on October 29, 2026. The offering began on May 21, 2025 and was first disclosed on June 24, 2025 under the company’s former name, AxoSim.
The original notice reported $1.775 million sold. A January 27, 2026 amendment increased that to $6.525 million; the latest filing adds $1,999,945 to the cumulative total and reports 10 investors, with no amount remaining. It does not identify when those additional subscriptions closed.
The company develops human neural tissue models for drug development. Its brain organoids and peripheral nervous system services help researchers assess neurological safety and therapeutic effects.